Discover Roquette’s latest innovations and our new Biopharma Innovation Center!
![](/46/pdcnewsitem/08/02/00/Discover-Roquettes-latest-innovations-and-our-new-Biopharma-Innovation-Center.jpg)
Roquette works closely with customers in the development of innovative pharmaceutical formulations and new biopharma solutions.
With a multidisciplinary expertise and more than 50 products, Roquette offers an extended range of starches and derivatives, sugars & polyols, with an exceptional potential for meeting your needs, wherever you are, for oral dosage, nutraceuticals & OTC, Injectables, Dialysis & Specialty APIs and Biopharma.
When it comes to raw materials for cell culture or excipients in your formulation, you now have an alternative option: Manage risk with a steady supply of confidence for your materials from a source who has sole custody of the supply chain. Roquette now offers multi-compendial grade materials for both upstream and downstream applications.
To develop innovations in BioPharma and beyond, we have recently expanded our Research & Development and Customer Technical Service teams to include facilities in Singapore’s Biopolis international research and development center. Now our deep expertise in formulation and applications science enables us to provide customers with even more localized project support around the world and in-depth training on-site. Laboratory and pilot equipment at these facilities help customers address their technical and innovation challenges.
From oral dosage excipients (Rx, Gx, nutraceuticals & OTC) and biopharma materials to injectables and dialysis solutions, Roquette is holding itself to the highest industry standards - providing consistency and reliability across every ingredient.
To learn more about our latest innovations, come and visit us on our booth # 10.2 A66 and join us also for our cocktail party on Tuesday 5th at 17.00!
![Roquette America Inc.](https://www.cphi-online.com/th265855-comp265855.png)
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance